Holistic Approach to Primary Care webinar is organized by eMedEvents and mainly focuses on the current developments in primary care. Topics include infectious diseases, palliative care, surgical procedures and medical practice.
Johnson & Johnson said on Wednesday (January 18) that it was pulling the plug on a late-stage global trial of an HIV vaccine after the shot was found ineffective
at preventing infections.
The failure of the trial marks yet another setback in the search for a vaccine against a virus known to mutate rapidly and find unique ways to evade the immune
system, and comes more than a year after another of J&J's HIV vaccine failed a study.
"It's not the outcome we had hoped for, unfortunately," said a spokesperson for the National Institute of Allergy and Infectious Diseases, a J&J partner in the trial.
"The development of a safe and effective HIV vaccine has been a considerable scientific challenge, but we will learn from this study and continue forward."
The trial involved administering two different types of a shot, which uses a cold-causing virus to deliver the genetic code of HIV, spread over four vaccination
visits in a year. J&J used similar technology for its COVID-19 vaccine.
The study, which began in 2019, was conducted at over 50 sites and included about 3,900 gay men and transgender people - groups that are considered vulnerable to
the infection.
The Pharmaceutical Services Negotiating Committee (PSNC) has urged community pharmacy to plan and ensure patients are able to access their prescription if they
have to close in an emergency situation for a short period.
It has prepared a guidance which can be undertaken by pharmacy in the event of a closure and the contractor's business can resume easily and effectively once the
emergency has passed.
In its guidance, PSNC has stated a few actions that can be taken by pharmacy in advance:
Plan ahead - be ready before a closure is needed. Don't wait until your pharmacy needs to be closed before you consider how you will manage and what you can put in
place to mitigate the impact.
Make sure your business continuity plan is up to date and relevant to the current situation. For example, try not to rely on family and friends as part of your plan;
if you're having to isolate because of infectious illness, your close contacts may need to do so as well.
Ensure your SOPs are accurate, up to date and easy-to-find for someone completely unfamiliar with your pharmacy. Emergency numbers will be crucial. Normal, everyday
business continuity issues are still going to arise and anyone on-site needs to know how to address them:
BioNTech and Pfizer are to start tests on humans of next-generation vaccines that protect against a wide variety of coronaviruses in the second half of the year.
Their experimental work on shots that go beyond the current approach include T-cell-enhancing shots, designed to primarily protect against severe disease if the
virus becomes more dangerous, and pan-coronavirus shots that protect against the broader family of viruses and its mutations.
In presentation slides posted on BioNTech's website for its investor day, the German biotech firm said its aim was to "provide durable variant protection".
The two companies are currently discussing with regulators enhanced versions of their established shot to better protect against the Omicron variant and its
sublineages.
The virus' persistent mutation into new variants that more easily evade vaccine protection, as well as waning human immune memory, have added urgency to the search
by companies, governments and health bodies for more reliable tools of protection.
As part of a push to further boost its infectious disease business, BioNTech said it was independently working on precision antibiotics that kill superbugs that
have grown resistant to currently available anti-infectives.
All adults aged 50 years and above are eligible for free flu jabs in England under the autumn Covid-19 booster programme, the Department of Health and Social
Care (DHSC) has announced.
"The flu virus could also be highly infectious at this time of year, so I am also announcing that those eligible for a free flu vaccination this year will include
everyone aged 50 and over, primary school children and secondary school pupils in years 7, 8 and 9, as well as people in clinical risk groups, unpaid carers and
household contacts of those who are immunosuppressed," said new health secretary Steve Barclay.
Commenting on the DHSC's announcement, CCA chief executive Malcolm Harrison said: "We welcome the decision to accept the advice of the JCVI on who can have free
Covid-19 boosters and flu jabs this autumn. Community pharmacies have turbo-charged the Covid-19 vaccination programme over the past 18 months and last year we
witnessed the most successful community pharmacy flu campaign ever."
The routine, twice-weekly asymptomatic Covid-19 testing by pharmacy staff can be paused from the end of August.
The health regulator announced that regular asymptomatic testing for Covid-19 will be paused in all remaining health and care settings from 31 August 2022.
Currently all pharmacy staff test twice-weekly for Covid-19, using a self-administered Lateral Flow Device (LFD) test at home.
"Prevalence of Covid-19 in the community has fallen and remains at a comparatively low level as we emerge from the current Omicron wave. This means that the
likelihood that individuals entering healthcare settings are infectious has also reduced and the relative risk of onward transmission into these settings is lower."
The UK Health Security Agency (UKHSA) has raised alarm over rising cases of extensively antibiotic-resistant Shigella infections, mainly in gay, bisexual,
and other men who have physical relationship with men (GBMSM).
There has been a 53 per cent increase in cases since the beginning of 2023, mostly driven by a cluster of antibiotic resistant strain called Shigella sonnei,
with 97 cases reported this year until November, compared to just four cases last year.
According to UKHSA, Shigella sonnei infections are difficult to treat as the strain does not respond to the antibiotics typically used to treat the bacteria.
While it has been found across England, cases are concentrated in London (45), the North West (21) and South East (12).
Shigella is an infectious gut infection that can cause symptoms like diarrhoea (sometimes mixed with blood), stomach cramps and fever, which are commonly
mistaken for food poisoning.
The World Health Organization said on Sunday (May 29) that monkey pox constitutes a "moderate risk" to overall public health at global level after cases were reported in countries where the disease is not typically found.
"The public health risk could become high if this virus exploits the opportunity to establish itself as a human pathogen and spreads to groups at higher risk of severe disease such as young children and immunosuppressed persons," WHO said.
As of May 26, a total of 257 confirmed cases and 120 suspected cases have been reported from 23 member states that are not endemic for the virus, the health agency
said in a statement. There has been no reported fatalities so far.
WHO also said that the sudden appearance of monkeypox at once in several non-endemic countries suggests undetected transmission for some time and recent amplifying events.
The agency added that it expects more cases to be reported as surveillance in endemic and non-endemic countries expands.
Monkeypox is an infectious disease that is usually mild, and is endemic in parts of west and central Africa. It is spread by close contact, so it can be relatively easily contained through measures such as self-isolation and hygiene.
A person in England has been diagnosed with a rare viral monkeypox infection thought to be linked to travel to West Africa, health authorities said at the weekend (May 7).
The UK Health Security Agency (UKHSA) said in a statement the case, in a person who had recently traveled to Nigeria, was being treated at an expert respiratory infectious disease unit at Guy's and St Thomas' NHS Foundation Trust in London.
"It is important to emphasise that monkeypox does not spread easily between people and the overall risk to the general public is very low," said Colin Brown, director of clinical and emerging infections at UKHSA.
Maintaining good personal hygiene is among the most effective defenses against gastrointestinal and infectious disorders such as the flu, and the common cold.
By using soap and water to wash your hands, you can prevent the spread of germs that can make you sick.
When it comes to your own health, basic personal hygiene can also assist protect you from infecting others. A typical personal hygiene consists of following habits:
Every day, washing your face and body
Washing your hands after using the bathroom with soap
Twice daily cleaning of the teeth
When you sneeze or cough, using a tissue (or your sleeve) to cover your mouth and nose
After touching pets and other animals, cleaning your hands
Here's what you can do to reduce the spread of infection through a basic personal hygiene:
Keeping Food In A Safe Environment
Before and after cooking, wash your hands. Thus, you won't be able to contaminate food and won't get sick or spread bacteria from food, such as raw meat
German biotechnology company BioNTech has signed a deal with the Department of Health and Social Care to enrol up to 10,000 patients in clinical trials by the
end of 2030 for personalised cancer therapies, the German drug maker said.
The multi-year collaboration is focused on cancer immunotherapies based on mRNA or other drug classes, infectious disease vaccines, and investments into expanding
the company's footprint in the UK, BioNTech said in a statement on Thursday (January 5).
Under the agreement, the parties plan to utilise UK's clinical trial network, genomics and health data assets, aiming to enrol the first cancer patient in the second
half of 2023, the company said.
At the European Conference of Clinical Microbiology & Infectious Diseases (ECCMID) this year in Copenhagen, Denmark, data on a test that may detect HIV,
hepatitis B, and hepatitis C from a single drop of blood are being presented.
Hepatitis B or C claim the lives of over a million people each year. Every year, 1.5 million individuals contract HIV, and 650,000 people pass away from HIV-related
causes.
The World Health Organisation has made the elimination of all three viruses by 2030 one of its global health strategies but new tests are necessary if case numbers
are to be reduced.
The most common test for hepatitis B, hepatitis C and HIV involves taking a blood sample from a vein using a needle. While this method works extremely well, there
is a potentially large reservoir of the three conditions in places where this method is not suitable.
This could be prisons, drug rehabilitation centres and homeless shelters, where the taking of venous blood samples isn't always suitable or countries in which the
shipping and refrigerated storage of blood samples can be challenging.
Alternatives include dried blood spot tests, in which a single spot of blood is tested for nucleic acid from the three viruses.
The UK government has awarded a £1.7 million contract to Ensilicated Technologies Ltd (EnsiliTech), a University of Bath spinout company dedicated to
making vaccines safer, to develop the world's first thermally stable mRNA vaccine.
mRNA vaccines have a huge potential to prevent infectious diseases and a range of previously unpreventable conditions, but currently, these vaccines require
ultracold storage, needing to be kept at -70 or even -80 °C.
The company's ensilication technology allows vaccines and other biological materials to be transported and stored without the use of refrigeration.
Dr Asel Sartbaeva, co-founder and CEO at EnsiliTech, believes that the technology could save tens of thousands of lives every year.
She commented: "We're so proud to have won this important government grant."
In a recent announcement, Mundipharma, a leading global pharmaceutical company, has announced its acquisition of all assets and rights related to
rezafungin from Cidara Therapeutics.
This solidified Mundipharma's dedication to managing infectious diseases and specialty care therapeutic areas, especially invasisve candidiasis which over
the 15 years has seen no new therapeutic developments underscoring for alternative options.
The FDA and MHRA approved rezafungin is a groundbreaking once-weekly echinocandin antifungal drug specifically designed for the treatment of invasive candidiasis
in adults.
While Mundipharma will oversee global commercialization efforts, Melinta Therapeutics will retain commercialization rights for rezafungin in the United States.
Moreover, the acquisition empowers the pharmaceutical company with global ownership of rezafungin, encompassing its ongoing development and distribution.
With scarlet fever currently circulating in England, the UK Health Security Agency (UKSHA) has urged parents to remain vigilant for potential symptoms in
children.
Also known as scarlatina, it is an infectious disease triggered by group A strep bacteria that can lead to symptoms such as fever, a sandpapery rash, sore throat
and swollen tonsils.
The latest data published by the UKHSA showed that a total of 19,528 cases of scarlet fever were reported in the 2023/24 season, of which 12,176 cases occurring
between 1 January and 24 March 2024.
While the number of cases recorded this year is lower than those recorded during the same period in 2023, which totaled 15,933 cases, it exceeds the average for
the previous five years.
"Scarlet fever is a common childhood illness, although it can affect anyone of any age," said Dr Theresa Lamagni at UKHSA.
Parents are advised to contact their GP practice or NHS111 when their GP is unavailable, if they suspect they or their child are experiencing symptoms of scarlet
fever.
Infectious Mononucleosis (IM) is an acute, self-limiting disease caused by the Epstein-Barr virus (EBV). Infection with EBV in early life in adults usually is asymptomatic. Diagnosis of IM is based on the evaluation of characteristic clinical symptoms and serological changes. Serological diagnosis of IM has been demonstrated by the detection of heterophile and EBV specific antibodies. It is a widely accepted practice among physicians to use the detection of heterophile antibodies as an aid in the diagnosis of IM.
The medical diagnostics industry is advancing at a fast-paced. The new innovations come with a promise to enhance the accuracy of detecting diseases...
Influenza, also known as the flu, is an infectious disease that is caused by the RN viruses, from the influenza virus's family. Fever, sore throat, chills, muscle pain, tiredness and general discomfort are among the most common symptoms of this infection. This disease may be fatal, especially for the young. There are various types of influenza and are grouped according to their genera.